Stock analysts at Leerink Partners assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Get Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set an "outperform" rating and a $28.00 price target on the stock. Leerink Partners' price objective would suggest a potential upside of 128.95% from the company's previous close.
Maze Therapeutics Price Performance
Maze Therapeutics stock traded down $0.49 during mid-day trading on Tuesday, hitting $12.23. 141,658 shares of the company were exchanged, compared to its average volume of 324,193. Maze Therapeutics has a 12-month low of $10.08 and a 12-month high of $17.00.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
